Semaphorin 3A induces cytoskeletal paralysis in tumor-specific CD8+ T cells

ABSTRACT
Semaphorin-3A (Sema3A) regulates tumor angiogenesis, but its role in modulating anti-tumor immunity is unclear. We demonstrate that Sema3A secreted within the tumor microenvironment (TME) suppresses tumor-specific CD8+ T cell function via Neuropilin-1 (NRP1), a receptor that is upregulated upon activation with T cells’ cognate antigen. Sema3A inhibits T cell migration, assembly of the immunological synapse, and tumor killing. It achieves these functional effects through hyper-activating the acto-myosin system in T cells leading to cellular paralysis. Finally, using a clear cell renal cell carcinoma patient cohort, we demonstrate that human tumor-specific CD8+ T cells express NRP1 and are trapped in Sema3A rich regions of tumors. Our study establishes Sema3A as a potent inhibitor of anti-tumor immunity.
Subject Area
- Biochemistry (10821)
- Bioengineering (8068)
- Bioinformatics (27381)
- Biophysics (14030)
- Cancer Biology (11165)
- Cell Biology (16106)
- Clinical Trials (138)
- Developmental Biology (8808)
- Ecology (13332)
- Epidemiology (2067)
- Evolutionary Biology (17399)
- Genetics (11705)
- Genomics (15963)
- Immunology (11061)
- Microbiology (26168)
- Molecular Biology (10680)
- Neuroscience (56746)
- Paleontology (422)
- Pathology (1737)
- Pharmacology and Toxicology (3012)
- Physiology (4569)
- Plant Biology (9669)
- Synthetic Biology (2699)
- Systems Biology (6997)
- Zoology (1515)